Cardiotoxicity Following Cancer Treatment

More than half of those born after 1960 will develop cancer during their lifetime. Fortunately, owing to improved diagnosis and treatment, cure rates have risen steadily over the last three decades. With an increased survivorship, more will experience adverse effects of cancer therapeutics on the he...

Descripción completa

Detalles Bibliográficos
Autores principales: Walls, GM, Lyon, AR, Harbinson, MT, Hanna, GG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Ulster Medical Society 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324172/
https://www.ncbi.nlm.nih.gov/pubmed/28298705
_version_ 1782510170328268800
author Walls, GM
Lyon, AR
Harbinson, MT
Hanna, GG
author_facet Walls, GM
Lyon, AR
Harbinson, MT
Hanna, GG
author_sort Walls, GM
collection PubMed
description More than half of those born after 1960 will develop cancer during their lifetime. Fortunately, owing to improved diagnosis and treatment, cure rates have risen steadily over the last three decades. With an increased survivorship, more will experience adverse effects of cancer therapeutics on the heart. As the oncologist’s focus begins to encompass the issues of cancer survivorship, awareness of the management of cardiac toxicity would be prudent for all physicians looking after patients with cancer.
format Online
Article
Text
id pubmed-5324172
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Ulster Medical Society
record_format MEDLINE/PubMed
spelling pubmed-53241722017-03-15 Cardiotoxicity Following Cancer Treatment Walls, GM Lyon, AR Harbinson, MT Hanna, GG Ulster Med J Review More than half of those born after 1960 will develop cancer during their lifetime. Fortunately, owing to improved diagnosis and treatment, cure rates have risen steadily over the last three decades. With an increased survivorship, more will experience adverse effects of cancer therapeutics on the heart. As the oncologist’s focus begins to encompass the issues of cancer survivorship, awareness of the management of cardiac toxicity would be prudent for all physicians looking after patients with cancer. The Ulster Medical Society 2017-01 /pmc/articles/PMC5324172/ /pubmed/28298705 Text en © The Ulster Medical Society, 2017 https://creativecommons.org/licenses/by-nc-sa/4.0/ UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk). The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited and the new creation is licensed under identical terms.
spellingShingle Review
Walls, GM
Lyon, AR
Harbinson, MT
Hanna, GG
Cardiotoxicity Following Cancer Treatment
title Cardiotoxicity Following Cancer Treatment
title_full Cardiotoxicity Following Cancer Treatment
title_fullStr Cardiotoxicity Following Cancer Treatment
title_full_unstemmed Cardiotoxicity Following Cancer Treatment
title_short Cardiotoxicity Following Cancer Treatment
title_sort cardiotoxicity following cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324172/
https://www.ncbi.nlm.nih.gov/pubmed/28298705
work_keys_str_mv AT wallsgm cardiotoxicityfollowingcancertreatment
AT lyonar cardiotoxicityfollowingcancertreatment
AT harbinsonmt cardiotoxicityfollowingcancertreatment
AT hannagg cardiotoxicityfollowingcancertreatment

Ejemplares similares